CALIFORNIA STD SCREENING RECOMMENDATIONS 2015

The following recommendations are based on guidelines for STD screening from the Centers for Disease Control and Prevention, United States Preventive Services Task Force, Infectious Disease Society of America, and the California Department of Public Health-STD Control Branch. In populations for whom no recommendations exist, screening should be based on risk factors, local epidemiology and prevalence of specific STDs in the particular clinical setting. **All women** diagnosed with chlamydia (CT), gonorrhea (GC), or trichomonas should be retested for repeat infection at 3 months after treatment. Men diagnosed with CT or GC should also be retested at 3 months. Retesting can also be performed opportunistically anytime the patient returns for care in the 1-12 months after treatment. Other factors to consider prior to screening are summarized in the footnotes below.

| | Population | STD Screening Recommendations | Frequency | Comments |
|-------|--|--|---|--|
| Women | Women < 25 years of age ¹⁻⁴ | CT and GC (vaginal, cervical, or urine) Other STDs according to risk. | Annually At least once, then repeat according to level of risk | CT/GC: consider screening more frequently for those at increased risk. |
| | Women 25 years of age and older ¹⁻⁴ | No routine screening for STDs. Screen according to risk. HIV | All women up to 64 years of age at least once, then repeat according to level of risk | Targeted CT/GC screening recommended for women with risk factors. See footnote 4. |
| | Pregnant women ^{1,3,5} | CT and GC (vaginal, cervical, or urine) | First trimester First trimester First trimester First trimester | Repeat screening for CT, GC, HIV, HBsAg in third trimester if at increased risk. Repeat syphilis screening recommended in third trimester if high risk or living in area of high morbidity, per local guidelines. |
| | HIV-positive women ^{1,6-9} | CT and GC (vaginal, cervical, or urine) | Annually Annually (if exposed) Annually (if exposed) Annually Annually | Repeat screening for CT, GC and syphilis every 3-6 months, if indicated by risk |
| | | Hepatitis B Surface Antigen (HBsAg) Hepatitis C | First visit First visit | |
| Men | Heterosexual men ³ | No routine screening for STDs. Screen according to risk. HIV | All men 13-64 years of age at least once, then annually if high-risk | Targeted screening for CT in high risk settings (e.g. corrections) or if risk factors (e.g. CT in past 24 months). |
| | Men who have sex with men (MSM) ^{1,6} | CT and GC (urine) CT and GC (rectal) GC (pharyngeal) Syphilis. HIV | Annually Annually (if exposed) Annually (if exposed) Annually Annually | Repeat screening for CT, GC, syphilis and HIV every 3-6 months, as indicated by risk. |
| | | Hepatitis B Surface Antigen (HBsAg) | At least once | |
| | HIV-positive men ⁶⁻⁸ | CT and GC (urine) CT and GC (rectal) GC, (pharyngeal) Syphilis | Annually Annually (if exposed) Annually (if exposed) Annually | Repeat screening for CT, GC and syphilis every 3-6 months, as indicated by risk. |
| | Treatment Guidelines. June | Hepatitis B Surface Antigen (HBsAg) Hepatitis C | First visit Annually | |

¹CDC. STD Treatment Guidelines. June 5, 2015 / 64(RR3);1-137.

⁹The use of highly sensitive and specific tests (e.g., nucleic acid amplification test (NAAT)) is recommended for detecting *Trichomonas vaginalis*.





²Human papillomavirus (HPV) testing is recommended as part of cervical cancer screening and management of cervical intraepithelial neoplasia. It is not recommended as part of routine STD screening or prior to initiating HPV vaccination. See the American Society for Colposcopy and Cervical Pathology (www.asccp.org) for further guidance.

³Screening for asymptomatic HSV-2 infection should be offered to select patients including those in partnerships or considering partnerships with HSV-2-infected individuals. Counseling should be provided to patients tested for HSV-2. Guidelines for the Use of Herpes Simplex Virus (HSV) Type 2 Serologies – California Department of Public Health. www.std.ca.gov
⁴Risk factors for CT or GC: prior CT or GC infection, particularly in past 24 months; more than one sex partner in the past year; suspicion that a recent partner may have had concurrent partners; new sex partner in past 3 months; exchanging sex for drugs or money in the past year; African American women up to age 30, and local factors such as community prevalence of infection.

⁵In pregnant women with a history of injection drug use or a history of blood transfusion or organ transplantation before 1992, screening for hepatitis C should be conducted. California Guidelines for STD Screening and Treatment in Pregnancy. www.std.ca.gov

⁶Routine hepatitis B vaccination is recommended for all HIV-infected patients and all MSM. Routine hepatitis A vaccination is recommended for all MSM. Prevaccination serologic testing may be considered, however if testing is not feasible in the current setting, routine vaccination should continue.

⁷Primary Care Guidelines for the Management of Persons Infected with Human Immunodeficiency Virus: 2013 Update by the HIV Medicine Association of the Infectious Disease Society of America. *Clinical Infectious Diseases* 2013; doi: 10.1093/cid/cit665.

Data are insufficient to recommend routine anal cancer screening with anal cytology among HIV-positive men and women. Some clinical centers perform anal cytology screening in populations at high-risk for anal cancer. Programmatic considerations such as availability of providers to perform diagnostic anoscopy in the case of abnormal results should be considered prior to initiating anal cancer screening.